Sentiment Summary
Recent Events
First half 2026 earnings results are expected to be released around August 26, 2026, expected. High importance is estimated due to the significant impact of previous earnings growth on stock volatility.
The ex-dividend date for the final cash dividend of HKD 0.25 per share for the fiscal year 2025 is July 21, 2026, scheduled.
The ex-dividend date for the proposed final dividend of HKD 0.05 per share is 2026-06-24, which is estimated to have a price impact of ≥1% scheduled.
Innovent will present obesity pipeline data at the ADA Scientific Sessions on June 5-8, 2026; this low-impact event is scheduled
Ex-dividend date of 2026-06-01 for final and special dividends, scheduled. (Estimated Low impact as dividend is standard).
The 48-week top-line results from the Phase 2 clinical trial of 'DD01', a MASH treatment, are scheduled to be presented at the European Association for the Study of the Liver (EASL) Congress 2026 (May 27-30) as a Late-Breaking Abstract; high impact is estimated due to the significant market potential for MASH treatments, which is expected.
Q1 2026 earnings release scheduled. Analysts forecast revenue of 7.52B HKD. Estimated Medium importance as earnings results typically drive significant price movement scheduled.
Q1 2026 earnings release on 2026-05-18 with high price impact expected based on results versus expectations scheduled.
1st Quarter 2026 earnings release scheduled for 2026-05-18. This release is under heightened scrutiny following the company's recent designation as an unfaithful disclosure corporation, with an estimated price impact of ≥5%.
CEO Dong Ki Lee is scheduled to present research on the company's RNAi platform for ophthalmic diseases at the TIDES USA 2026 conference on May 14, 2026; a 5% price impact is estimated due to potential clinical data updates, scheduled.
Received clinical trial approval from China's NMPA for HS-10541 tablets on 2026-05-13; estimated 5% impact due to innovative drug pipeline expansion.
The company is expected to receive Investigational New Drug (IND) approval from China's NMPA for SKB118; this pipeline milestone is estimated to have a 5% price impact as it validates the drug's potential expected.
Repurchased 1.78 million shares for approximately HKD 10.05 million on 2026-05-13. This is estimated to have a price impact of ≥1% expected.
Announced that the first subject has been dosed in the Phase 1 clinical trial of ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor for autoimmune diseases. Early-stage clinical progress is estimated to have a low market impact (>1%).
Global strategic collaboration and licensing agreement with Bristol-Myers Squibb (BMS) for 13 early-stage programs in oncology, hematology, and immunology, with a potential value of up to $15.2 billion and upfront/near-term payments of $950 million; the high deal value is estimated to result in a price impact exceeding 10%, scheduled
Announced the acquisition of French distributor Giphar on 2026-05-12 to expand its European network to 9,000 pharmacies; this strategic expansion justifies a medium importance estimate, scheduled.
Announced that its associate, Legend Biotech (LEGN), reported strong Q1 2026 results on May 12, 2026, with CARVYKTI net sales increasing 62% year-over-year to approximately $597 million and a narrowed net loss.
Announced the exercise of its option to co-develop and share costs and profits/losses for its core drug candidate DB-1311/BNT324 in the U.S. market with partner BioNTech.
Executive President and Global Chief Medical Officer, Yongjiang Hei, was reported to have officially resigned to start his own venture. Estimated Low importance as executive changes in large firms often have limited immediate price impact.
Launched the TurboCHO™ Protein Expression Kit, a new reagent for antibody expression, at the PEGS Summit in Boston on May 12, 2026, aimed at accelerating drug discovery.
South Korea's Financial Supervisory Service (FSS) officially stated it is closely monitoring Samchundang Pharm following recent controversies over public disclosures and stock price volatility on 2026-05-11. The FSS also announced plans to issue new disclosure guidelines for bio-pharma companies by the end of June 2026, with an expected price impact of ≥10%.
Announced an exclusive strategic collaboration with GSK to commercialize bepirovirsen in mainland China on 2026-05-11; analysts forecast high sales potential and a price impact of ≥10% forecasted.
Announced that its ADC drug SYS6010 was granted another Breakthrough Therapy Designation in China for treating esophageal squamous cell carcinoma. Estimated Low importance as breakthrough designations are positive but early-stage regulatory milestones.
Scheduled to present clinical data for its 'Grabody-T' platform, including results for Ragistomic (ABL503) and Givastomic (ABL111), at the PEGS Boston conference from May 11-15, 2026 scheduled.
IBI363 is expected to receive its third Breakthrough Therapy Designation from the NMPA on May 10, 2026; this clinical milestone's low market impact is expected
HS-20093 granted Breakthrough Therapy Designation by China's NMPA for esophageal squamous cell carcinoma on 2026-05-09; estimated 5% impact from accelerated approval path.
Alteogen Q1 2026 earnings announcement: revenue of KRW 71.6 billion and operating profit of KRW 39.3 billion. Results driven by upfront payments from GSK and Biogen. High impact expected due to significant profit growth expected.
The NMPA is expected to approve the Mazdutide pen for type 2 diabetes on May 8, 2026; this core product approval's medium market impact is expected
The sNDA for sacituzumab tirumotecan (sac-TMT) in combination with pembrolizumab is expected to be accepted for review by China's NMPA; this regulatory progress is estimated to have a 5% price impact expected.
Announced Q1 2026 earnings on May 8, 2026, with revenue of KRW 13.1 billion, primarily from technology transfer fees. The company reported holding approximately KRW 190 billion in cash and cash equivalents.
Q1 2026 results on 2026-05-07 showed a total revenue decrease of 18.7% and a net profit decrease of 42% year-over-year; High importance assigned due to the significant earnings miss likely causing a >10% price impact.
Announced on May 7, 2026, that Class 1 innovative drug UBT38006 Injection received implied approval for clinical trials from China's NMPA. This regulatory milestone is estimated to result in a price impact of ≥1% expected.